Overview

  • Product nameTAK 715
  • Description
    Potent p38 MAPK inhibitor
  • Biological descriptionPotent p38 MAPK inhibitor (IC50 = 7.1 nM at p38 MAPKα). Additionally inhibits Wnt-3a stimulated β-catenin signaling and shows cross-reactivity with casein kinase Iδ and ε. Antirheumatic. Active in vivo.
  • Purity> 99%

Properties

    References for TAK 715 (ab120989)

    This product has been referenced in:
    • Verkaar F  et al. Inhibition of Wnt/ß-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Id/?. Chem Biol 18:485-94 (2011). Read more (PubMed: 21513885) »
    • Roberts PJ & Der CJ Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-310 (2007). Read more (PubMed: 17496923) »
    • Miwatashi S  et al. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J Med Chem 48:5966-79 (2005). Read more (PubMed: 16162000) »

    See 0 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab120989.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"